AR115159A1 - Vesículas extracelulares modificadas y usos de las mismas - Google Patents

Vesículas extracelulares modificadas y usos de las mismas

Info

Publication number
AR115159A1
AR115159A1 ARP190101375A ARP190101375A AR115159A1 AR 115159 A1 AR115159 A1 AR 115159A1 AR P190101375 A ARP190101375 A AR P190101375A AR P190101375 A ARP190101375 A AR P190101375A AR 115159 A1 AR115159 A1 AR 115159A1
Authority
AR
Argentina
Prior art keywords
protein
exosomes
luminal surface
therapeutic
exosome
Prior art date
Application number
ARP190101375A
Other languages
English (en)
Original Assignee
Codiak Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Codiak Biosciences Inc filed Critical Codiak Biosciences Inc
Publication of AR115159A1 publication Critical patent/AR115159A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5184—Virus capsids or envelopes enclosing drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C12N2509/10—Mechanical dissociation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Botany (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente se refiere a exosomas terapéuticos enriquecidos en proteínas que están presentes en la superficie luminal de exosomas. La presente descripción proporciona métodos para manufacturar exosomas enriquecidos en proteínas que están presentes en la superficie luminal de los exosomas, método para asociar un péptido o proteína terapéutica a la superficie luminal de exosomas y método de uso, por ejemplo, métodos de uso terapéutico o de diagnóstico. Los métodos de manufactura implican la generación de exosomas con superficie luminal modificada que incluyen una o más de las EV, por ejemplo, proteínas de exosomas en concentraciones mayores que las observadas en los exosomas tipo salvaje, una modificación o un fragmento de la proteína de EV, por ejemplo, exosoma, o una proteína de fusión de la proteína de EV, por ejemplo, exosoma y una carga útil, por ejemplo, molécula biológicamente activa tal como una proteína terapéutica. Reivindicación 1: Una vesícula extracelular aislada (EV), caracterizada porque comprende una molécula biológicamente activa enlazada a una proteína de andamiaje, en donde la proteína de andamiaje comprende un dominio de extremo N-terminal (ND) y un dominio de efector (ED), en donde el ND está asociado con la superficie luminal de la EV y el ED está asociado con la superficie luminal de la EV por una interacción iónica, en donde el ED comprende al menos dos lisinas contiguas (Lys) en secuencia.
ARP190101375A 2017-11-17 2019-05-23 Vesículas extracelulares modificadas y usos de las mismas AR115159A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762587767P 2017-11-17 2017-11-17
US201862634750P 2018-02-23 2018-02-23
PCT/US2018/061679 WO2019099942A1 (en) 2017-11-17 2018-11-16 Compositions of engineered exosomes and methods of loading luminal exosomes payloads

Publications (1)

Publication Number Publication Date
AR115159A1 true AR115159A1 (es) 2020-12-02

Family

ID=66534134

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190101375A AR115159A1 (es) 2017-11-17 2019-05-23 Vesículas extracelulares modificadas y usos de las mismas

Country Status (11)

Country Link
US (3) US20200347112A1 (es)
JP (2) JP2021503300A (es)
KR (1) KR20200091390A (es)
CN (1) CN111511384A (es)
AR (1) AR115159A1 (es)
AU (1) AU2018367670A1 (es)
CA (2) CA3234784A1 (es)
IL (1) IL274634A (es)
MX (1) MX2020004883A (es)
SG (1) SG11202003871SA (es)
WO (1) WO2019099942A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3684381B8 (en) * 2017-09-21 2022-12-07 Codiak BioSciences, Inc. Production of extracellular vesicles in single-cell suspension using chemically-defined cell culture media
WO2019246591A1 (en) 2018-06-21 2019-12-26 Codiak Biosciences, Inc. Methods of measuring extracellular vesicles and nanoparticles in complex matrices by light scattering
CA3119720A1 (en) * 2018-11-16 2020-05-22 Codiak Biosciences, Inc. Engineered extracellular vesicles and uses thereof
SG11202108389QA (en) * 2019-02-04 2021-08-30 Codiak Biosciences Inc Membrane protein scaffolds for exosome engineering
JP2022531095A (ja) * 2019-04-17 2022-07-06 コディアック バイオサイエンシーズ， インコーポレイテッド エキソソーム及びａａｖの組成物
US20240024220A1 (en) * 2019-05-11 2024-01-25 Youngsuk Yi Neurotoxin compositions and methods
EP3994158A1 (en) 2019-07-03 2022-05-11 Codiak BioSciences, Inc. Extracellular vesicles targeting t cells and uses thereof
CA3147365A1 (en) 2019-08-14 2021-02-18 Joanne LIM Extracellular vesicle-nlrp3 antagonist
WO2021030769A1 (en) 2019-08-14 2021-02-18 Codiak Biosciences, Inc. Extracellular vesicles with nras antisense oligonucleotides
CN114641570A (zh) 2019-08-14 2022-06-17 科迪亚克生物科学公司 具有靶向kras的反义寡核苷酸的细胞外囊泡
JP2022544289A (ja) 2019-08-14 2022-10-17 コディアック バイオサイエンシーズ， インコーポレイテッド Ｓｔａｔ６を標的とする細胞外小胞－ａｓｏ構築物
EP4013878A1 (en) 2019-08-14 2022-06-22 Codiak BioSciences, Inc. Extracellular vesicle-aso constructs targeting cebp/beta
EP4034276A1 (en) 2019-09-25 2022-08-03 Codiak BioSciences, Inc. Methods of producing extracellular vesicles
WO2021062058A1 (en) 2019-09-25 2021-04-01 Codiak Biosciences, Inc. Sting agonist comprising exosomes for treating neuroimmunological disorders
EP4034150A1 (en) 2019-09-25 2022-08-03 Codiak BioSciences, Inc. Sting agonist comprising exosomes combined with il-12 displaying exosomes for treating a tumour
WO2021062057A1 (en) 2019-09-25 2021-04-01 Codiak Biosciences, Inc. Exogenous loading of exosomes via lyophilization
CN114727947A (zh) 2019-09-25 2022-07-08 科迪亚克生物科学公司 细胞外囊泡组合物
US20220390437A1 (en) 2019-11-05 2022-12-08 Codiak Biosciences, Inc. High-throughput chromatography screening for extracellular vesicles
EP4090974A1 (en) 2020-01-17 2022-11-23 Codiak BioSciences, Inc. Cholesterol assays for quantifying extracellular vesicles
US20230097907A1 (en) * 2020-01-27 2023-03-30 Mantra Bio, Inc. Non-naturally occurring vesicles comprising a chimeric vesicle localization moiety, methods of making and uses thereof
JP2023512562A (ja) 2020-02-05 2023-03-27 ダイアデム バイオセラピューティクス インコーポレイテッド 人工シナプス
WO2021184020A1 (en) 2020-03-13 2021-09-16 Codiak Biosciences, Inc. Methods of treating neuroinflammation
WO2021184017A1 (en) 2020-03-13 2021-09-16 Codiak Biosciences, Inc. Extracellular vesicles for treating neurological disorders
WO2021184021A1 (en) 2020-03-13 2021-09-16 Codiak Biosciences, Inc. Extracellular vesicle-aso constructs targeting pmp22
WO2021189047A2 (en) 2020-03-20 2021-09-23 Codiak Biosciences, Inc. Extracellular vesicles for therapy
WO2021228832A1 (en) 2020-05-11 2021-11-18 Erytech Pharma Red cell extracellular vesicles (rcevs) containing cargoes and methods of use and production thereof
US20230220068A1 (en) 2020-06-05 2023-07-13 Codiak Biosciences, Inc. Anti-transferrin extracellular vesicles
JP2023537070A (ja) * 2020-08-07 2023-08-30 アミカス セラピューティックス インコーポレイテッド 小胞を標的とするタンパク質及びその使用
WO2022040223A1 (en) 2020-08-17 2022-02-24 Codiak Biosciences, Inc. Methods of treating cancer
WO2022066898A2 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Methods of producing extracellular vesicles
US20240241020A1 (en) 2020-09-23 2024-07-18 Lonza Sales Ag Process for preparing extracellular vesicles
EP4217087A2 (en) 2020-09-23 2023-08-02 Codiak BioSciences, Inc. Process for preparing extracellular vesicles
WO2022066883A1 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Extracellular vesicles comprising kras antigens and uses thereof
WO2022076596A1 (en) 2020-10-06 2022-04-14 Codiak Biosciences, Inc. Extracellular vesicle-aso constructs targeting stat6
CN112410304A (zh) * 2020-11-12 2021-02-26 天津大学 一种基因修饰的外泌体及其制备方法和应用
CN112903999A (zh) * 2021-01-20 2021-06-04 蚌埠医学院第一附属医院（蚌埠医学院附属肿瘤医院） 一种用于纳米流式细胞仪检测的外泌体的制备方法及应用
KR20230147125A (ko) 2021-02-17 2023-10-20 론자 세일즈 아게 세포외 소포-nlrp3 길항제
IL305172A (en) 2021-02-17 2023-10-01 Lonza Sales Ag Methods for loading extracellular vesicles
EP4304566A1 (en) 2021-04-01 2024-01-17 Lonza Sales AG Extracellular vesicle compositions
WO2023027082A1 (ja) * 2021-08-23 2023-03-02 積水化学工業株式会社 ペプチド結合ハイブリッドリポソームエクソソーム、ペプチド結合エクソソーム、これらを含む組成物及びその形成方法
KR20240082391A (ko) 2021-10-14 2024-06-10 론자 세일즈 아게 세포외 소포 생산을 위한 변형된 생산자 세포
WO2023085821A1 (ko) * 2021-11-10 2023-05-19 주식회사 씨케이엑소젠 엑소좀 기반 항바이러스 백신 및 이의 제조방법
WO2023091905A1 (en) * 2021-11-19 2023-05-25 Elmaleh David R Targeted extracellular vesicles and methods of use thereof
WO2023183794A2 (en) * 2022-03-24 2023-09-28 Mercury Bio, Inc. Direct production of sirnas in saccharomyces boulardii and packaging in extracellular vesicles (evs) for targeted gene silencing
CN117126886A (zh) * 2022-05-20 2023-11-28 谛邈生物科技(北京)有限公司 一种实现工程化EVs功能蛋白模块化装载的核酸构建体及其应用
CN116656705A (zh) * 2023-04-18 2023-08-29 河南中医药大学第一附属医院 pHLIP-Lamp2b-1/2融合蛋白重组质粒及其构建、应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005500049A (ja) * 2001-07-17 2005-01-06 ノバルティス アクチエンゲゼルシャフト 有機化合物
JP5713325B2 (ja) * 2009-04-17 2015-05-07 アイシス イノヴェイション リミテッド 遺伝物質の送達用の組成物
US9149542B2 (en) * 2010-07-01 2015-10-06 Aeon Medix Inc. Microvesicles derived from cell protoplast and use thereof
GB201121069D0 (en) * 2011-12-07 2012-01-18 Isis Innovation Delivery system
WO2016172598A1 (en) * 2015-04-22 2016-10-27 The Broad Institute Inc. Exosomes and uses thereof
US10624849B2 (en) * 2015-09-28 2020-04-21 Northwestern University Targeted extracellular vesicles comprising membrane proteins with engineered glycosylation sites
US20190008902A1 (en) * 2015-12-30 2019-01-10 The Regents Of The University Of California Methods for enhanced production and isolation of cell-derived vesicles
WO2017147719A1 (en) * 2016-03-04 2017-09-08 Exerkine Corporation Method for treating neuropathy

Also Published As

Publication number Publication date
AU2018367670A1 (en) 2020-05-07
WO2019099942A1 (en) 2019-05-23
MX2020004883A (es) 2020-08-06
CA3234784A1 (en) 2019-05-23
CA3082588A1 (en) 2019-05-23
KR20200091390A (ko) 2020-07-30
CN111511384A (zh) 2020-08-07
US20240000944A1 (en) 2024-01-04
US20200347112A1 (en) 2020-11-05
JP2024015074A (ja) 2024-02-01
IL274634A (en) 2020-06-30
US20190151456A1 (en) 2019-05-23
JP2021503300A (ja) 2021-02-12
SG11202003871SA (en) 2020-05-28

Similar Documents

Publication Publication Date Title
AR115159A1 (es) Vesículas extracelulares modificadas y usos de las mismas
CL2021001278A1 (es) Vesículas extracelulares modificadas y sus usos
CL2020000428A1 (es) Preparación de exosomas terapéuticos mediante el uso de proteínas de membrana.
PE20190352A1 (es) Proteinas de fusion gdf 15 y usos de estas
CL2018000232A1 (es) Mezcla de péptidos (divisional solicitud 201601405)
CR20180027A (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer.
CL2011003003A1 (es) Composicion tensioactiva reconstituida que comprende un polipeptido análogo a la proteína surfactante c nativa, un polipeptido análogo a la proteína surfactante b nativa, un fosfolipido monoinsaturado y un fosfolipido saturado, útil para el tratamiento del síndrome de dificultad respiratoria.
CR20170419A (es) Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer.
BR112017001940A2 (pt) proteínas de fusão de interleucina-2/receptor alfa de interleucina-2 e processos de uso
ES2722773T3 (es) Polipéptidos de fHbp meningocócicos modificados
CR20180174A (es) Nuevos péptidos, combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer
CO6640254A2 (es) Método para preparar anticuerpos con propiedades mejoradas
CL2018003319A1 (es) Compuestos de mic-1 y usos de estos.
AR113422A2 (es) Agentes tensioactivos reconstituidos que tienen propiedades mejoradas
PE20190394A1 (es) Anticuerpos anti-c5 y metodos de uso
CL2021001162A1 (es) Proteínas de fusión fc il-22 y métodos de uso. (divisional de solicitud 202001944)
AR076977A1 (es) Proteinas precursoras repetitivas autoensambladas
PE20200697A1 (es) Polipeptidos de serina proteasa 1 de tipo membrana modificada (mtsp-1) y metodos de uso
PE20191711A1 (es) Peptidos y combinaciones de los mismos para el uso en la inmunoterapia contra diversos tipos de cancer
CO2019013768A2 (es) Compuestos de mic-1 y usos de estos
CO6210831A2 (es) Nuevas proteinas h5 moleculas de acido nucleico y vectores que las codifican y su uso medicinal
BR112019011462A2 (pt) peptídeo coagonista de gip/glp-1, e, peptídeo para uso no tratamento e/ou profilaxia da doença de alzheimer clínica.
CO2022003218A2 (es) Péptido q-er
CO2017012675A2 (es) Péptidos lipidados resistentes a proteasas
BR112015019568A2 (pt) Peptídeo isolado, composição compreendendo o mesmo e uso do mesmo